Anika Therapeutics (ANIK) Operating Margin: 2010-2025
Historic Operating Margin for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -11.62%.
- Anika Therapeutics' Operating Margin fell 1135.00% to -11.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.99%, marking a year-over-year decrease of 3449.00%. This contributed to the annual value of -4.25% for FY2024, which is 495.00% down from last year.
- Per Anika Therapeutics' latest filing, its Operating Margin stood at -11.62% for Q3 2025, which was up 21.54% from -14.81% recorded in Q2 2025.
- Over the past 5 years, Anika Therapeutics' Operating Margin peaked at 24.07% during Q2 2021, and registered a low of -852.09% during Q4 2023.
- For the 3-year period, Anika Therapeutics' Operating Margin averaged around -88.35%, with its median value being -11.62% (2025).
- Its Operating Margin has fluctuated over the past 5 years, first crashed by 56,309bps in 2022, then spiked by 84,978bps in 2024.
- Over the past 5 years, Anika Therapeutics' Operating Margin (Quarterly) stood at -25.47% in 2021, then tumbled by 56,309bps to -588.55% in 2022, then tumbled by 26,353bps to -852.09% in 2023, then soared by 84,978bps to -2.30% in 2024, then tumbled by 1,135bps to -11.62% in 2025.
- Its Operating Margin stands at -11.62% for Q3 2025, versus -14.81% for Q2 2025 and -16.37% for Q1 2025.